HCW Biologics Inc

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. Its lead autoimmune candidate, HCW9302, is an IL-2-based fusion immunotherapeutic in Phase 1 clinical trials for alopecia areata that targets CD25 to activate and expand regulatory T cells. The company is also advancing HCW11-018b, a tetravalent T-cell engager targeting tissue factor-expressing solid tumors including gynecologic and pancreatic cancers, with a pre-IND meeting requested from the FDA. HCW Biologics has developed commercial-ready molecules such as HCW9206 for use as reagents in CAR-T therapy manufacturing, positioning itself at the intersection of cell therapy production and immunotherapy development. The company has entered into licensing agreements including a worldwide license with Beijing Trimmune Biotech for its HCW11-006 molecule. The company trades on NASDAQ under the ticker HCWB and recently effected a 1-for-6 reverse stock split to maintain listing compliance. Updated Aug 14, 2026